Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Wesley W. Bodie"'
Autor:
Xin-Yan Pei, Yun Dai, Jessica Felthousen, Shuang Chen, Yukie Takabatake, Liang Zhou, Leena E Youssefian, Michael W Sanderson, Wesley W Bodie, Lora B Kramer, Robert Z Orlowski, Steven Grant
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e89064 (2014)
The anti-apoptotic protein Mcl-1 plays a major role in multiple myeloma (MM) cell survival as well as bortezomib- and microenvironmental forms of drug resistance in this disease. Consequently, there is a critical need for strategies capable of target
Externí odkaz:
https://doaj.org/article/3c9abcdb83b1404890faef5d609aa231
Autor:
Paul Dent, Yukie Takabatake, Lora Kramer, Jorge A. Almenara, Xin-Yan Pei, Leena E. Youssefian, Steven Grant, Yun Dai, Wesley W. Bodie, Jessica Felthousen, Shuang Chen
Publikováno v:
Blood. 118:5189-5200
Effects of Chk1 and MEK1/2 inhibition were investigated in cytokinetically quiescent multiple myeloma (MM) and primary CD138+ cells. Coexposure to the Chk1 and MEK1/2 inhibitors AZD7762 and selumetinib (AZD6244) robustly induced apoptosis in various
Autor:
Liang Zhou, Wesley W. Bodie, Jessica Felthousen, Robert Z. Orlowski, Shuang Chen, Xin Yan Pei, Lora Kramer, Michael W. Sanderson, Leena E. Youssefian, Yun Dai, Steven Grant, Yukie Takabatake
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 3, p e89064 (2014)
PLoS ONE, Vol 9, Iss 3, p e89064 (2014)
The anti-apoptotic protein Mcl-1 plays a major role in multiple myeloma (MM) cell survival as well as bortezomib- and microenvironmental forms of drug resistance in this disease. Consequently, there is a critical need for strategies capable of target
Autor:
Xin-Yan Pei, Yun Dai, Jessica Felthousen, Shuang Chen, Yukie Takabatake, Leena E. Youssefian, Wesley W. Bodie, Lora B. Kramer, Robert Z. Orlowski, Steven Grant
Publikováno v:
Cancer Research. 73:3390-3390
Mcl-1 is a critical survival factor for human multiple myeloma (MM) cells, and also confers resistance to various anti-MM agents, including bortezomib (btz). We have previously reported that exposure of MM cells to Chk1 inhibitors elicits activation
Autor:
Yukie Takabatake, Lora Kramer, Yun Dai, Wesley W. Bodie, Xin-Yan Pei, Shuang Chen, Paul Dent, Steven Grant, George Almenara, Leena E. Youssefian
Publikováno v:
Cancer Research. 71:5367-5367
One potential barrier to successful multiple myeloma (MM) treatment stems from the observation that it generally represents a low growth fraction disease with cells resting in a quiescent, non-proliferative state (i.e., < 5% of cells actively cycling
Immune Reconstitution Inflammatory Syndrome Presenting as Mycobacterium Avium Complex Lymphadenitis.
Autor:
Matusz-Fisher A; Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA. Ashley.Matuszfisher@carolinashealthcare.org., Bodie W; Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA., Montgomery T; Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA.
Publikováno v:
Journal of general internal medicine [J Gen Intern Med] 2017 Jun; Vol. 32 (6), pp. 712-713. Date of Electronic Publication: 2016 Dec 20.